HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

BIO

Bio-Rad Laboratories, Inc. (S&P 500)

Healthcare — Medical Devices

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Hold 2.8 / 5 5 analysts
$331.00
+$14.59 (+4.61%)
Target: $297.00 (-10.3%)
Sign in to add BIO to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$8.86B
P/E Ratio (TTM)55.07
Forward P/E34.05
EPS (TTM)$6.01
Dividend Yield-
Profit Margin6.52%
Revenue Growth1.10%
ROE2.50%
Debt/Equity20.12
Recommendation Hold 2.8
Analyst Target$297.00
Analysts5
Indexes S&P 500

Technical Indicators

RSI (14)86.9
Beta1.09
SMA 20$301.86
SMA 40$297.14
52-Week High$343.12
52-Week Low$236.73
50-Day Avg$294.13
200-Day Avg$295.16
Avg Volume392.9K
Volume416.0K

Performance Analysis

NEUTRAL

BIO presents a mixed picture with both positive and negative indicators.

+ Showing strength at 89% of its 52-week range.
- RSI at 86.9 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- P/E of 55.1 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 1.1% year-over-year.
~ Wall Street consensus is "Hold" from 5 analysts.
- Average analyst target of $297.00 implies 10.3% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:00 UTC

Back to Screener Export Report